Teladoc Health, Inc. (TDOC) Cash Flow Statement

The most important signal in this dataset is the gap between net income and operating cash flow: losses of roughly -$25M to -$93M per quarter coexist with operating inflows of $9.5M to $110M, which suggests that large non-cash charges such as the $90M-$100M quarterly D&A and stock-based compensation are driving the accounting loss rather than an operating cash drain. Investors should monitor whether this cash generation reflects genuine operating economics or timing effects, since the OCF/NI ratio cannot be interpreted as a quality-of-earnings measure while earnings remain negative. The 2026Q1 quarter, where operating cash flow fell to $9.5M, warrants further investigation into whether the cushion is durable.

The trajectory of FCF suggests an unstable base, as the recent quarters show FCF of $75.9M in 2026Q3 and $63.7M in 2026Q2 but these follow a trough that included a negative quarter, making a trend assessment difficult. The margin profile of roughly 10% to 13% in most recent periods is meaningful only if sustained, and it appears partly supported by working capital inflows rather than purely by earnings power. Analysts should treat the recent FCF level as a provisional rather than established run rate.

The pattern suggests that capital spending is discretionary and irregular rather than a steady maintenance requirement, since D&A of $87M to $100M per quarter far exceeds typical CapEx outlays in most periods. This gap may indicate that the depreciation base reflects prior-cycle investments being allowed to run down, or that a significant portion of the asset base is intangible and amortizing, which would not require replacement capex in the same way. The 2024Q3 positive CapEx figure is an anomaly that warrants further investigation rather than interpretation as underlying capital efficiency.

Because working capital contributed materially to several of the stronger OCF quarters, including the 2026Q3 result, the reported operating cash flow may overstate the repeatable earnings power of the core business. The -$35.6M outflow in 2026Q1, coinciding with the weakest OCF of $9.5M, suggests that collection timing or payables management may be a meaningful source of quarterly volatility. Investors should monitor whether these swings reverse over time or persist as a structural pattern.

This divergence suggests that the company's economic reality is better captured by cash metrics than by GAAP earnings, but it also raises the question of how much of the reported cash generation is sustainable given that accounting losses persist. The magnitude of the 2024Q2 charge relative to the other quarters indicates that non-recurring items are distorting the earnings trend, which limits how far the net loss can be treated as a clean operating signal. Investors should monitor whether the gap narrows as impairment and restructuring effects roll off.